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Translational Relevance: 1 Clear cell renal cell carcinoma (ccRCC) is an enigma of the tumor microenvironment studies Lymphocyte Activation Gene-3 (LAG-3), which is co-expressed with PD-1 on CD8+ tumor-7 infiltrating lymphocytes in melanoma (23), and together with PD-1 synergistically regulates T 8 cell function (24). We expected immune check points high ccRCC patients to have a worse 9 prognosis than the immune check point low.
10
In these newly described scenarios where CD8+ T cell infiltration correlates with poor prognosis,
11
it is important to define the combination of immune-based biomarkers that will predict patients' 12 prognosis and further guide immunotherapeutic approaches. This study aims to investigate the Table S1 (14) .
12
In addition, expression data for 496 primary ccRCC samples with complete follow-up was 13 downloaded from The Cancer Genome Atlas' KIRC study, using version 2 of the normalized Table S2 . IF stained slides were scanned after 9 secondary antibody incubation and mounting. For the IHC staining, peroxidase activity was 10 detected using 3-amino-9-ethylcarbazole substrate (AEC) or Novared and alkaline phosphatase 11 using alkaline phosphatase substrate III (Vector Laboratories).
Tests of the specificity and sensitivity of PD-1, PD-L1, PD-L2 and LAG-3 monoclonal antibodies 13 for IHC experiments were performed utilizing generated FFPE cell pellets from transfected (n=10) from different oncology indications were also tested using the above mentioned protocols.
18
Normal human FFPE tonsil sections for PD-1, LAG-3, PD-L2 and normal placenta for PD-L1
19
were used as positive controls (Fig. S1 ). cutoff were computed. The cutoff that minimized the P-value of a Log-rank test for DFS was 17 retained, and the corresponding P-value was corrected using the method published by Altman et 18 al. (32) . These cutoffs were later used to segregate patients into two groups, and their associated univariately associated with prognosis were included in the multivariate Cox regression analysis.
1
The duration of follow-up was calculated from the date of nephrectomy or metastasectomy to the 2 date of death or last follow-up. The density of CD8+ T cells in the tumor center (TC) had no prognostic impact (Table S4 ). The other pathologic variables including TNM (data not shown).
10
An independent cohort of lung metastases of ccRCC, in which the negative impact of high 11 densities of CD8+T cells on OS had been previously described using semi-quantitative counting 12 techniques (14), was reanalyzed using a quantitative approach on 51 cases. The OPv for CD8+ T P=3.17x10 -7 , that displayed the lowest P-value (Fig. 1C) . Based on the OPv for IFNG, patients (Table S4 ). The Fuhrman grade 13 was associated with the PD-1+ cell density in the IM (Fig. S2 ).
14 Out of the 80 patients, 9 were considered as LAG-3 High (subdivided by the OPv cutoff) in the IM 15 and they displayed a shorter DFS (P=0.02, Fig. 2A ), and did not reach significance for the OS
16
(P=0.07, Fig. 2A ). The density of LAG-3+ cells in the TC was not significantly associated with 17 patients DFS or OS (Table S4 ). Representative pictures of the IHC staining of highly and poorly
18
PD-1 and LAG-3 infiltrated lesions are shown in Fig. S3A and Fig. S3B , respectively. Table S4 ). while PD-L1 (CD274) was not (P=0.67) (Fig. 2D ).
19
It has been reported that IFN-γ can induce PD-L1 expression on tumor cells (27). We found a 20 significant positive correlation between the gene expression of IFNG with PD-L1 (R=0.13,
21
P=0.004) and with PD-L2 (R=0.42, P=2.2x10 -16 ) in the TCGA cohort (Fig. 3A) . In addition, a 22 significant positive correlation was found between the densities of PD-1+ and CD8+ T cells (Fig. 3B and 3C ). An even stronger 2 correlation was found at the gene expression level between PD-1 and LAG-3 (R=0.81, P=0.002), (Fig. 3B and 3C ). In accordance with all these observations, we 5 also detected the presence of triple positive CD8+/PD-1+/LAG-3+ cells in 6 out of 7 cases from 6 the CD8
High group of primary tumors by immunofluorescence on paraffin sections (representative 7 pictures are displayed in Fig. 3D ). Table S4 ).
22
Research. 
Patients with high densities of PD-1+ lymphocytes and PD-L1+ and/or PD-L2+ tumor cells in 1 their ccRCC lung metastases (n=12) had the worst prognosis as assessed by OS (OS, P=0.003, 2 Fig. 4B ). The patients that met these criteria had 3.1 times more risk to die after metastasectomy 3 than patients who did not (risk ratio 3.1; 95% CI 1.28-6.66; P=0.003, Table S4 ). Strikingly, 100% LAG-3+ cells (R=0.71, P<0.0001).
10
In conclusion, the combined analysis of the expression of PD-1, PD-L1 and PD-L2 identified a 11 group of patients with a high risk of progression and death in primary and in an independent 12 cohort of metastatic ccRCC. (Table S4) . TLS-DC densities in the TC 
were not associated with prognosis. Interestingly, high densities of TLS-DC (based on the OPv 1 cut-off) in the IM identified a group of patients with good prognosis among the CD8 High group for 2 both DFS (P=0.001, Fig. 5A ) and OS (P=0.03, Fig. 5A ). shorter DFS (P<0.0001) and OS (P=0.001, Fig. 5D ). In order to define the independent prognostic significance of the previously mentioned immune- Interestingly, we found that these cells do not express activation and co-stimulatory markers and 12 they are probably recruited directly from the blood into the tumor stroma -contrary to the usual expression of these molecules is related with a chronic inflammatory and highly suppressive 7 process that is unselectively recruiting CD8+ and NTLS-DC cell from the circulation, and overall 8 is associated with a poor prognosis.
9
Another characteristic of ccRCC is the lack of prognostic significance of the immune cells in the 10 TC. While CD8+, PD-1+, LAG-3+, and NTLS-DC densities in the IM of the primary tumors 11 were associated with poor prognosis, they had no prognostic significance when present in the TC.
12
In CRC, both regions are important to define the best immune score, which correlates with 
In summary, we identify a subset of primary and metastatic ccRCC patients characterized by (1) Performed the experiments and cell quantification: N.A.G., G.S., L.L., I.N., A.L.
21
Contributed reagents/materials/analysis tools: G.S., F.T., G.J.F. 
CD8
High group (A, bottom) or NTLS-DC in the entire cohort (B, bottom). 
